Key Takeaways
What Is Infusion Therapy?
Infusion therapy is a method of putting fluids, including drugs, into the bloodstream; it is also called intravenous (IV) infusion[1]. Medicare's definition of home infusion also covers drugs given subcutaneously, under the skin, through a pump[2].
Infusion therapy is used across medicine, and it has a narrower role in treating mental illness. In psychiatry today, the term mostly refers to IV ketamine for treatment-resistant depression, an off-label use that the VA describes as increasing[8].
The Centers for Medicare & Medicaid Services (CMS) lists four parts of a home infusion: the drug (for example, antivirals or immune globulin), equipment such as a pump, supplies such as tubing and catheters, and nursing services that train patients and caregivers[2].
IV therapy and infusion therapy overlap but are not identical. The NCI treats infusion and intravenous infusion as synonyms[1], while Medicare's home infusion benefit also counts subcutaneous pump infusions that never enter a vein[2].
Where Is Infusion Therapy Given?
Infusions can be given in a health care facility or at home. CMS notes that home infusion typically requires coordination among patients, physicians, hospital discharge planners, health plans, home infusion pharmacies and, where involved, home health agencies[2].
Medicare created a dedicated home infusion therapy benefit through Section 5012 of the 21st Century Cures Act, enacted December 13, 2016, with coverage effective January 1, 2021[2]. The benefit pays for professional services, including nursing, training, education and remote monitoring, for certain drugs given intravenously or subcutaneously through a pump[2].
At home, visiting nurses typically train the patient or a caregiver to self-administer the drug, explain side effects and visit periodically to check the infusion site and change dressings[2].
The psychiatric infusions discussed below have been facility-based. Before August 2023, the only FDA-approved drug treatment specific to postpartum depression was an IV infusion given by a health care provider in certain health care facilities[11]. VA-funded ketamine sessions are supervised by a physician, nurse or other qualified professional throughout[8].
What Are the Risks and Side Effects of Infusion Therapy?
Risks come from two places: the IV line and the drug running through it. Peripheral IV catheters are the most commonly used invasive medical device in health care, with an overall failure rate of 35% to 50%, according to a 2023 expert consensus review[3].
Most of those complications are not infections. The review lists phlebitis (vein inflammation), infiltration or extravasation (fluid leaking into nearby tissue), occlusion, leakage and dislodgement as the usual problems[3]. Local site infections and bloodstream infections can also occur[3].
Drug effects depend on what is infused. For the psychiatric infusions below, the main concerns are sedation, loss of consciousness, dissociation and blood pressure changes, which is why both require on-site monitoring[8][9].
Which Mental Health Conditions Use Infusion Therapy?
The two infusions with a U.S. regulatory record in depression are IV ketamine and brexanolone. Their paths ran in opposite directions.
IV ketamine is FDA-approved as a general anesthetic: a Schedule III controlled substance given by IV or intramuscular injection. It is not FDA-approved for the treatment of any psychiatric disorder[4]. Depression treatment uses lower, subanesthetic doses as an off-label use[8].
Brexanolone (Zulresso). First approved in 2019 for postpartum depression, brexanolone was given as a continuous IV infusion over 60 hours (2.5 days)[9]. In clinical studies in adults, 4% of patients lost or had altered consciousness during the infusion, compared with 0% on placebo[9].
The manufacturer told the FDA the drug was no longer marketed, and approval was withdrawn as of April 14, 2025[10]. Current options are covered in postpartum depression treatment.
Two related drugs are not infusions. Esketamine (Spravato), a ketamine derivative, is a nasal spray approved with an oral antidepressant for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior[4]. Zuranolone (Zurzuvae), approved in August 2023, was the first oral medication for postpartum depression in adults[11].
Does Ketamine Infusion Therapy Work for Depression?
The largest head-to-head trial, published in the New England Journal of Medicine in 2023, randomized 403 patients with nonpsychotic treatment-resistant depression at five U.S. sites to IV ketamine twice a week or electroconvulsive therapy (ECT) three times a week, each for 3 weeks[5].
55.4% of patients in the ketamine group responded, compared with 41.2% in the ECT group, meeting the trial's test for noninferiority[5]. Remission on the MADRS was 37.9% with ketamine and 21.8% with ECT[5].
The trial had limits. It was open-label with no placebo, excluded psychotic depression, enrolled mostly outpatients (89%), and did not study maintenance treatment[5]. The authors note ECT has been shown to work better in older adults, in depression with psychosis and in inpatient settings; see electric shock therapy (ECT) for that evidence[5].
A 2026 meta-analysis in JAMA Psychiatry pooled 26 randomized trials with 1,166 patients in a major depressive episode[6]. After a single infusion, depressive symptoms were lower than in control groups at 4 hours, 24 hours, 3 days and 1 week (standardized mean difference −1.15 at 24 hours)[6].
Suicidal symptoms were also lower than in controls at 24 hours and at 1 month after a single infusion[6]. The authors concluded that longer-term outcomes are not well established[6]. For how infusions compare with daily pills, see antidepressant drug classes.
Patients with treatment-resistant depression who responded to 3 weeks of IV ketamine in a 2023 randomized trial
That compared with 41.2% for ECT among 365 treated patients. The trial was open-label and did not test maintenance treatment, so how long the benefit lasts is unknown.
"55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response"
What Happens During a Ketamine Infusion Session?
Under VA community care criteria effective January 1, 2025, each ketamine treatment session runs about two hours[8]. Patients arrive one hour early for vital signs, IV placement and mood testing; the rest is a 40-minute infusion followed by recovery time[8].
Staff supervise the full session, and the Clinician-Administered Dissociative States Scale (CADSS) is given before discharge[8]. In the 2023 trial, ketamine was dosed at 0.5 mg per kilogram of body weight over 40 minutes, and 92.3% of the ketamine group completed all six sessions[5].
Side effects reported in trials
Ketamine was associated with dissociation, while ECT was associated with musculoskeletal effects[5]. Moderate or severe headache occurred in 8.2% of ketamine patients and severe or prolonged high blood pressure in 3.1% during the treatment phase[5].
Patient-rated memory scores at the end of treatment were better in the ketamine group than in the ECT group[5]. In the 2026 meta-analysis, serious adverse events such as hospitalizations and deaths were unrelated to the interventions, and other adverse events such as headache were transient[6].
For the related nasal drug, the FDA requires a boxed warning covering sedation, dissociation, respiratory depression, and abuse and misuse, plus at least two hours of monitoring after each dose in a certified setting[4].
Dissociation
A break in how the mind handles information, disconnecting from thoughts, feelings, memories, surroundings and sense of identity. Dissociative symptoms are among the most commonly reported side effects of IV ketamine and are measured with the CADSS before patients go home[8].
Related Terms
Source: U.S. Department of Veterans Affairs, 2025
Who Qualifies for Ketamine Infusions, and What Do Guidelines Say?
The 2022 VA/DoD guideline for major depressive disorder suggests ketamine or esketamine as an augmentation option for patients who have not responded to several adequate medication trials, a "weak for" recommendation[7]. The same guideline suggests against either drug as a first medication[7].
The VA estimates that about 30% of people diagnosed with major depressive disorder do not reach remission despite multiple antidepressants[8]. The treatment-resistant depression page tracks how common that is.
The VA's community care criteria set a higher bar. A veteran must have unipolar major depressive disorder, have not fully responded to four adequate antidepressant trials from different classes or have severe suicidal depression, score 15 or higher on the PHQ-9, and have been considered for ECT where appropriate[8].
IV ketamine is not recommended under those criteria for people with a current or past history of schizophrenia, schizoaffective disorder or bipolar disorder, dementia, uncontrolled hypertension (above 160 systolic or 90 diastolic), pregnancy, or current or previous ketamine misuse[8]. Rates of depression among veterans are on the veterans and depression page.
Coverage outside the VA is less defined. The VA notes that no Medicare coverage determinations exist for IV ketamine for treatment-resistant depression[8].
Frequently Asked Questions
Sources & References
- National Cancer Institute. Definition of infusion. NCI Dictionary of Cancer Terms. Published 2011. Accessed October 2026. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/infusion [Link]
- Centers for Medicare & Medicaid Services. Home Infusion Therapy/Home IVIG Services. CMS. Published 2026. Accessed October 2026. https://www.cms.gov/medicare/payment/fee-for-service-providers/home-infusion-therapy [Link]
- Zingg W, Barton A, Bitmead J, et al. Best practice in the use of peripheral venous catheters: a scoping review and expert consensus. Infection Prevention in Practice. Published 2023. Accessed October 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC9995289/ [Link]
- Warning letter: Keta Med Lab / www.ketamedlab.com (725154). U.S. Food and Drug Administration. Published 2026. Accessed October 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/keta-med-lab-wwwketamedlabcom-725154-06232026 [Link]
- Anand A, Mathew SJ, Sanacora G, et al. Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine. Published 2023. Accessed October 2026. https://www.nejm.org/doi/full/10.1056/NEJMoa2302399 [Link]
- Shim SR, Jeong HS, Bommersbach TJ, et al. Ketamine infusions and rapid reduction of suicidal and depressive symptoms in major depressive episode: a systematic review and meta-analysis. JAMA Psychiatry. Published 2026. Accessed October 2026. https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2026.0612 [Link]
- U.S. Department of Veterans Affairs, U.S. Department of Defense. VA/DoD clinical practice guideline for the management of major depressive disorder: provider summary. VA/DoD. Published 2022. Accessed October 2026. https://www.healthquality.va.gov/guidelines/MH/mdd/VADoDMDDCPG_ProviderSummary_Final_508_updated.pdf [Link]
- Veterans Health Administration Office of Integrated Veteran Care. Clinical determination and indication: intravenous ketamine for treatment resistant depression (CDI 00030). U.S. Department of Veterans Affairs. Published 2025. Accessed October 2026. https://www.va.gov/COMMUNITYCARE/docs/providers/CDI/IVC-CDI-00030.pdf [Link]
- ZULRESSO (brexanolone) injection, for intravenous use: prescribing information. U.S. Food and Drug Administration. Published 2022. Accessed October 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211371s007lbl.pdf [Link]
- Food and Drug Administration. Sage Therapeutics, Inc.; withdrawal of approval of a new drug application for ZULRESSO (brexanolone) solution. Federal Register. Published 2025. Accessed October 2026. https://www.federalregister.gov/documents/2025/03/14/2025-04101/sage-therapeutics-inc-withdrawal-of-approval-of-a-new-drug-application-for-zulresso-brexanolone [Link]
- FDA approves first oral treatment for postpartum depression. U.S. Food and Drug Administration. Published 2023. Accessed October 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-treatment-postpartum-depression [Link]